These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 27525990)

  • 1. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.
    Girgis RR; Slifstein M; D'Souza D; Lee Y; Periclou A; Ghahramani P; Laszlovszky I; Durgam S; Adham N; Nabulsi N; Huang Y; Carson RE; Kiss B; Kapás M; Abi-Dargham A; Rakhit A
    Psychopharmacology (Berl); 2016 Oct; 233(19-20):3503-12. PubMed ID: 27525990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [
    Slifstein M; Abi-Dargham A; Girgis RR; Suckow RF; Cooper TB; Divgi CR; Sokoloff P; Leriche L; Carberry P; Oya S; Joseph SK; Guiraud M; Montagne A; Brunner V; Gaudoux F; Tonner F
    Psychopharmacology (Berl); 2020 Feb; 237(2):519-527. PubMed ID: 31773210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone).
    Vernaleken I; Fellows C; Janouschek H; Bröcheler A; Veselinovic T; Landvogt C; Boy C; Buchholz HG; Spreckelmeyer K; Bartenstein P; Cumming P; Hiemke C; Rösch F; Schäfer W; Wong DF; Gründer G
    J Clin Psychopharmacol; 2008 Dec; 28(6):608-17. PubMed ID: 19011428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO.
    Graff-Guerrero A; Mamo D; Shammi CM; Mizrahi R; Marcon H; Barsoum P; Rusjan P; Houle S; Wilson AA; Kapur S
    Arch Gen Psychiatry; 2009 Jun; 66(6):606-15. PubMed ID: 19487625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Dopamine D3 and D2 Receptor Occupancies by a Single Dose of Blonanserin in Healthy Subjects: A Positron Emission Tomography Study With [11C]-(+)-PHNO.
    Tateno A; Sakayori T; Kim WC; Honjo K; Nakayama H; Arakawa R; Okubo Y
    Int J Neuropsychopharmacol; 2018 Jun; 21(6):522-527. PubMed ID: 29346639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo.
    Narendran R; Slifstein M; Guillin O; Hwang Y; Hwang DR; Scher E; Reeder S; Rabiner E; Laruelle M
    Synapse; 2006 Dec; 60(7):485-95. PubMed ID: 16952157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of dopamine D
    Sakayori T; Tateno A; Arakawa R; Kim WC; Okubo Y
    Psychopharmacology (Berl); 2021 May; 238(5):1343-1350. PubMed ID: 33180175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography.
    Seneca N; Finnema SJ; Laszlovszky I; Kiss B; Horváth A; Pásztor G; Kapás M; Gyertyán I; Farkas S; Innis RB; Halldin C; Gulyás B
    Psychopharmacology (Berl); 2011 Dec; 218(3):579-87. PubMed ID: 21625907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
    Citrome L
    Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo binding of antipsychotics to D3 and D2 receptors: a PET study in baboons with [11C]-(+)-PHNO.
    Girgis RR; Xu X; Miyake N; Easwaramoorthy B; Gunn RN; Rabiner EA; Abi-Dargham A; Slifstein M
    Neuropsychopharmacology; 2011 Mar; 36(4):887-95. PubMed ID: 21178982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study.
    Suzuki T; Graff-Guerrero A; Uchida H; Remington G; Caravaggio F; Borlido C; Pollock B; Mulsant B; Deluca V; Ismail Z; Mamo D
    Psychopharmacology (Berl); 2013 Jul; 228(1):43-51. PubMed ID: 23417515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study.
    Fervaha G; Caravaggio F; Mamo DC; Mulsant BH; Pollock BG; Nakajima S; Gerretsen P; Rajji TK; Mar W; Iwata Y; Plitman E; Chung JK; Remington G; Graff-Guerrero A
    Psychopharmacology (Berl); 2016 Oct; 233(21-22):3803-3813. PubMed ID: 27557949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Separating dopamine D
    Smart K; Gallezot JD; Nabulsi N; Labaree D; Zheng MQ; Huang Y; Carson RE; Hillmer AT; Worhunsky PD
    Neuroimage; 2020 Jul; 214():116762. PubMed ID: 32201327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A positron emission tomography occupancy study of brexpiprazole at dopamine D
    Girgis RR; Forbes A; Abi-Dargham A; Slifstein M
    Neuropsychopharmacology; 2020 Apr; 45(5):786-792. PubMed ID: 31847007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task.
    Suridjan I; Rusjan P; Addington J; Wilson AA; Houle S; Mizrahi R
    J Psychiatry Neurosci; 2013 Mar; 38(2):98-106. PubMed ID: 23010256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
    Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
    Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Occupancy of Dopamine D3 and D2 Receptors by Buspirone: A [11C]-(+)-PHNO PET Study in Humans.
    Le Foll B; Payer D; Di Ciano P; Guranda M; Nakajima S; Tong J; Mansouri E; Wilson AA; Houle S; Meyer JH; Graff-Guerrero A; Boileau I
    Neuropsychopharmacology; 2016 Jan; 41(2):529-37. PubMed ID: 26089182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine.
    Kiss B; Némethy Z; Fazekas K; Kurkó D; Gyertyán I; Sághy K; Laszlovszky I; Farkas B; Kirschner N; Bolf-Terjéki E; Balázs O; Lendvai B
    Drug Des Devel Ther; 2019; 13():3229-3248. PubMed ID: 31571826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice.
    Rabiner EA; Slifstein M; Nobrega J; Plisson C; Huiban M; Raymond R; Diwan M; Wilson AA; McCormick P; Gentile G; Gunn RN; Laruelle MA
    Synapse; 2009 Sep; 63(9):782-93. PubMed ID: 19489048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.